Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Ocuphire Pharma, Inc. | brhc10021462_10k.htm |
| EX-32.1 - EXHIBIT 32.1 - Ocuphire Pharma, Inc. | brhc10021462_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Ocuphire Pharma, Inc. | brhc10021462_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Ocuphire Pharma, Inc. | brhc10021462_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Ocuphire Pharma, Inc. | brhc10021462_ex21-1.htm |
| EX-10.43 - EXHIBIT 10.43 - Ocuphire Pharma, Inc. | brhc10021462_ex10-43.htm |
| EX-10.42 - EXHIBIT 10.42 - Ocuphire Pharma, Inc. | brhc10021462_ex10-42.htm |
| EX-10.41 - EXHIBIT 10.41 - Ocuphire Pharma, Inc. | brhc10021462_ex10-41.htm |
| EX-10.38 - EXHIBIT 10.38 - Ocuphire Pharma, Inc. | brhc10021462_ex10-38.htm |
| EX-4.11 - EXHIBIT 4.11 - Ocuphire Pharma, Inc. | brhc10021462_ex4-11.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-252715) and Form S-8 (No. 333-249978, 333-217627, 333-189240, and 333-129294) of Ocuphire Pharma, Inc., of our
report dated March 10, 2021, relating to the consolidated financial statements of Ocuphire Pharma, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Detroit, MI
March 10, 2021